Revolutionizing the treatment of
ischemic stroke and heart attack,
re-establishing blood flow faster,
without bleeding, soon in the ambulance
Thrombolytic Science (TSci) is a private, clinical stage, vascular medicine & biotech company
Current treatment options for patients experiencing a stroke or heart attack are limited and delay the
re-establishment of blood flow.
TSci is dedicated to transforming standards of care, by bringing a simple intravenous biotherapy to the patient, closer to the time of onset.
TSci's bio-inspired solution is
A low dose, efficacious, safer dual thrombolytic Rx
Based on a clinically validated mechanism
To be given on suspicion of a stroke or heart attack
TSci recently completed a Phase 1 clinical study confirming the safety and tolerability of its novel tPA / HisproUK dual regimen.
TSci's dual regimen is currently being tested in a Phase 2 clinical trial in ischemic stroke patients.
tPA's biological role is limited to degrading the surface of the clot.
With TSci’s regimen, once this occurs, the small amount of tPA used is rapidly cleared from the blood flow. HisproUK, TSci's compound, exclusively targets the now degraded clot and dissolves it.
Should there be no degraded clot, as in the case of stroke mimics or a hemorrhagic stroke, HisproUK will remain safely in its inactive pro enzymatic form before being cleared in minutes from the blood flow.
TSci's thrombolytic regimen could therefore be given safely on simple suspicion of an ischemic stroke, as soon as possible after stroke onset.
Management & Directors
Alexis Wallace, MScEng, MBA
Chief Executive Officer,
Co-founder & Board member
Chief Scientific Officer,
of the Board
Chairman of the Court,
London School of Hygiene
& Tropical Medicine
Professor of Medicine, Hematology
Adjunct Professor, Neurology,
Harvard Medical School, Former Chief Medical Officer, Chairman & Founder, InfraReDx
1985 Nobel Peace Prize
President & CEO,
for Clinical Research
Professor of Medicine,
Harvard Medical School
Chairman & Founder, PERFUSE